U.S. Food and Drug Administration Commissioner Scott Gottlieb, who will leave his post in April 2019, has taken action on a number of health and medical issues during his two years at the agency—more so than critics thought he would, according to a March 5, 2019 Xconomy article.
During his tenure, Gottlieb approved a record number of treatments and drugs and has pushed policies to curb opioid addiction and teen vaping.
The Xconomy article quoted a tweet from Ashish Jha, director of the Harvard Global Health Institute, in which he said Gottlieb’s resignation is “terrible news for public health” and called him “a ray of sunshine—advocating for vaccines, smarter drug policy, more generics, tackling vaping and tobacco.”
Read the Xconomy article: Two Years and Done: FDA Commissioner Gottlieb To Resign